(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
Mont Blanc road tunnel reopens to traffic after 15 weeks of repairs- As juries turn against social media for harming kids, Big Tech's invincibility starts to show cracks
- Vote In favor of Your Favored Pizza Cover
- An 'explosion' of solo-agers are struggling with rising costs and little support: 'I'm flying without a net'
- The most effective method to Keep up with Proficient Handshakes in a Computerized World
- How Mars' ancient lakes grew shields of ice to stay warm as the Red Planet froze
- The Solution to Ecological Protection: Saving Nature for People in the future
- The Fate of Rest: Patterns in Shrewd Beds
- High velocity Internet services for Metropolitan Regions
